Prellis Biologics has raised $8.7M

Posted on Updated on

According to Dr. Alex Morgan, Principal at Khosla Ventures and Dr. Melanie Matheu, Prellis Biologics’ co-founder and CEO, “Regenerative medicine has made enormous leaps in recent decades. However, to create complete organs, we need to build higher-order structures like the vascular system. Prellis’ optical technology provides the scaffolding necessary to engineer these larger masses of tissues. With our investment in Prellis, we’re supporting an initiative that will ultimately produce a functioning lobe of the lung, or even a kidney, to be used in addressing an enormous unmet global need. Human tissue engineering is the ability to build complex tissues with working vascular systems. The future of regenerative medicine revolves around harnessing the power of our own cells as therapeutics and building the tissues to keep them alive. Khosla Ventures is the perfect investor to support our merging of deep tech and cutting-edge regenerative medicine. With this technology in hand, we can begin to ask questions about real 3D cell biology that have never been asked before.”

PRELLIS BIOLOGICS rings without background.png building life with light

EurekAlert! Science NewsA service of the American Association for the Advancement of Science

2 thoughts on “Prellis Biologics has raised $8.7M

    Lori M-I said:
    August 1, 2019 at 11:25 pm

    That’s incredible. I really hope that the financials around this kind of technology don’t create a barrier for people of all means to access this technology once it is fully realized.

    babl responded:
    August 2, 2019 at 6:23 pm

    Yes indeed, If we all love good things from 3D printing. Everything will be inexpensive and affordable. Medical too:)

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.